NovaDrop Flush Device

An automatic flush for the IV set

NovaDrop is designed to start the saline flush as soon as the medication infusion ends.

Why NovaDrop

Illustration of an IV set full of medication

Reduce the volume left in the IV set

Medication can remain in the IV set after an infusion ends, and is often discarded with the set^{1 2 3}. NovaDrop is designed to reduce it to a clinically acceptable level.

Adherence to guidelines

NovaDrop is designed to strictly adhere to the guidelines that recommend flushing the IV set after intermittent infusions^{4 5}.

IV container on a pole with NovaDrop Flush Device connected below it

Automatic saline flush

NovaDrop is designed to ensure reliable flush initiation, without a separate manual step.

IV container, NovaDrop Flush Device and IV set lying side by side

Broad infusion compatibility

Developed for gravity- and pump-driven infusions at clinically relevant flow rates.

Cooper DM, Rassam T, Mellor A. Non-flushing of IV administration sets: an under-recognised under-dosing risk. Br J Nurs. 2018;27(14 Suppl):S4–S12. doi:10.12968/bjon.2018.27.14.S4
Bolla B, Buxani Y, Wong R, Jones L, Dube M. Understanding IV antimicrobial drug losses: the importance of flushing infusion administration sets. JAC Antimicrob Resist. 2020;2(3):dlaa061. doi:10.1093/jacamr/dlaa061
Rout J, Brysiewicz P, Essack S. Antimicrobial infusion practices within intensive care units: carbapenem infusion preparation and administration process errors. Intensive Crit Care Nurs. 2025;86:103786. doi:10.1016/j.iccn.2024.103786
Nickel B, Gorski L, Kleidon T, et al. Infusion Therapy Standards of Practice, 9th ed. J Infus Nurs. 2024;47(1S Suppl 1):S1–S285. doi:10.1097/NAN.0000000000000532
National Infusion and Vascular Access Society (NIVAS). Intravenous administration of medicines to adults: guidance on “IV-line flushing”, version 5. June 2023. https://vascular-access.files.svdcdn.com/production/images/NIVAS-flushing-guidelines-V5-June-2023.pdf

Technical specifications

Category	Specification	Value
Product	Trade name	NovaDrop Flush Device
	Device type	Pre-filled, single-use
Contents	Solution	0.9% Sodium Chloride Injection, USP
	Fill volume	30 ± 1 mL
Sterility	Sterility	Terminally sterilized
Connectivity	Connections	IV spike and access port, dimensions based on ISO 18250-7
Operating principle	Infusion types	Gravity-driven and pump-driven
	Mode of operation	Automatic flush initiation
Use conditions	IV container volume	50 mL to 1,000 mL
	Infusion rate	50 mL/h to 1,000 mL/h
	Container type, gravity-driven	Collapsible IV containers only
	Container type, pump-driven	Collapsible or semi-rigid IV containers
Regulatory / use	Intended prescription status	Rx only, prescription device (21 CFR 801 Subpart D)

Disclaimer

NovaDrop is an investigational medical device currently in development. It has not yet been cleared or approved by the U.S. Food and Drug Administration, CE marked under EU regulations, or authorized by any other regulatory body, and is not available for commercial sale or clinical use. The information on this website is provided for informational purposes only and does not constitute a claim regarding the safety, effectiveness, or availability of the product. Product specifications, timelines, and regulatory status are subject to change.

About us

Founded in 2022, Droplet IV (DropNordic IV ApS) is a Copenhagen-based medical device company developing automated IV set flushing technology. Its first product is NovaDrop Flush Device. Total funding exceeds USD 5 million, including more than USD 3 million in non-dilutive grants. In 2025, a USD 2 million round led by medtech-focused family offices and angel investors was closed.

Droplet IV is ISO 13485 certified, and NovaDrop Flush Device has been included in the FDA's Safer Technologies Program (STeP). The device is in the final phase of development, with manufacturing planned to start in 2027.

The DropNordic IV team seated together at the company office in Copenhagen

Meet the team

We're a small team based in Copenhagen, working together across engineering, quality, regulatory and clinical expertise. Close collaboration is a priority in everything we do.